fiboflapon

Fiboflapon is a potent, orally bioavailable small molecule inhibitor of 5-lipoxygenase activating protein (FLAP), developed primarily for the treatment of asthma and other inflammatory conditions. By binding to FLAP, fiboflapon blocks the synthesis of leukotrienes—potent inflammatory mediators derived from arachidonic acid—which play a key role in diseases such as asthma and potentially other inflammatory disorders. Excessive leukotriene production is implicated in exacerbating inflammation, with links to increased risk for myocardial infarction and stroke. Fiboflapon was originally developed by Amira Pharmaceuticals and later by GSK. It reached up to Phase II clinical trials for asthma but development appears to have been discontinued for both asthma and cardiovascular indications[1][2][3][4][5][6].

Brand names

fiboflapon

Other names

fiboflapon sodium